Pharmaceutical giant Novartis is to raise its shareholding in specialty eye care products manufacturer Alcon and execute the most expensive acquisition in medtech history. The deal, worth a total $38.5bn, would see Basel, Switzerland-based Novartis become a majority shareholder of ...
Please Login to read the full article.
